Browse > Article
http://dx.doi.org/10.14368/jdras.2017.33.1.1

A proposal of injection points of botulinum toxin into temporal region for chronic migraine  

Kim, Young Gun (Department of Orofacial Pain and Oral Medicine, Department of Anatomy, College of Dentistry, Yonsei University)
Bae, Jung Hee (Department of Orofacial Pain and Oral Medicine, Department of Anatomy, College of Dentistry, Yonsei University)
Kim, Seong Taek (Department of Orofacial Pain and Oral Medicine, Department of Anatomy, College of Dentistry, Yonsei University)
Publication Information
Journal of Dental Rehabilitation and Applied Science / v.33, no.1, 2017 , pp. 1-6 More about this Journal
Abstract
Botulinum toxin (BoNT) injections have been used not only in the field of cosmetic surgery such as forehead and eye wrinkle treatment but also in the treatment of chronic migraine, dystonia, spasticity, temporomandibular disorders (TMD). BoNT injections are the only approved therapies to date for prophylactic treatment of chronic migraine patients. Unlike the previously known paralysis of motor neurons, the mechanism of action for migraine is to block the release of non-cholinergic neurotransmitters such as substance P, CGRP, and glutamate, which are associated with peripheral sensitization and neurogenic inflammation in the sensory nerve, it is hypothesized that the signal is blocked. This review focuses on the analgesic effects of BoNT and suggests the direction for the development of injection methods for chronic migraine patients.
Keywords
botulinum toxin; pain; migraine; chronic headache;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599-609.   DOI
2 Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808.   DOI
3 U.S. Food and Drug Administration. FDA approves Botox to treat chronic migraine. Available from: https://wayback.archive-it.org/7993/20170112032340/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ ucm229782.htm (updated 2017 Feb 1).
4 Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985;12:314-6.   DOI
5 Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013;306:124-46.   DOI
6 Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011;51:1573-7.   DOI
7 Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400-4.   DOI
8 Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi 2001;105:218-22.
9 Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488-96.   DOI
10 Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93.   DOI
11 Filipovic B, Matak I, Bach-Rojecky L, Lackovi Z. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PloS One 2012;7:e29803.   DOI
12 Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011;186:201-7.   DOI
13 Baumel JJ, Vanderheiden JP, McElenney JE. The auriculotemporal nerve of man. Am J Anat 1971; 130:431-40.   DOI
14 Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010;50:1406-18.   DOI
15 Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the treatment of headache. Headache 2013;53 Suppl 2:54-61.   DOI